Apollon Formularies plc Apollon CEO Keynote speaker at Cannabis Conference

TIDMAPOL

Apollon Formularies plc

05 September 2022

5 September 2022

Apollon Formularies Plc

Chairman and CEO of Apollon is a Keynote speaker at the Cannabis Science Conference in Baltimore

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international pharmaceutical company trading on the Aquis Stock Exchange, is pleased to announce that Dr. Stephen Barnhill, Chairman and CEO of Apollon, is an invited keynote speaker at the Cannabis Science Conference ("CSC"), being held in Baltimore on 14-16 September 2022. Dr. Barnhill will deliver a presentation on the "Unique Combination of Cannabis and Mushrooms for the Treatment of Cancer" at 3:40 pm EDT/20:40 pm BST on 15 September.

CSC is the world's largest and fastest growing cannabis science event with a specialised focus on medical cannabis, analytical science, cultivation science, psychedelic science, hemp, and CBD. The conferences bring together a wide range of experts within the cannabis industry, including research scientists, medical practitioners, policy makers, instrument manufacturers and testing labs. The event aims to improve cannabis science and education. No new information related to Apollon will be released during the session.

Stephen Barnhill , MD, Chairman and CEO of Apollon Formularies plc , stated: "I am honoured to have been invited to address the upcoming Cannabis Science Conference, a world-leading medical cannabis event. It will serve as an opportunity to showcase Apollon's compelling third-party testing results which showed its proprietary medical cannabis formulations successfully killing nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. This endorsement by CSC is significant for Apollon, as it further strengthens our credibility and will improve our visibility, particularly in North America."

Interested parties can register for the event via the website: www.cannabisscienceconference.com

- Ends -

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies

   Tel:                                                      [phone] 
   Stene Jacobs                                       [e-mail] 

BlytheRay (Financial PR/IR-London)

   Tel:                                                       [phone] 
   Tim Blythe/Megan Ray                        [e-mail] 

About Apollon Formularies and Apollon Formularies Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALIMMTMTJMTLT

(END) Dow Jones Newswires

September 05, 2022 02:00 ET (06:00 GMT)